
PPD
Healthcare · Drug Manufacturers - Specialty & Generic · $16.61B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 27, 2021 | After the close | 0.38 | 0.43 | +12.5% |
| Jul 28, 2021 | After the close | 0.35 | 0.39 | +11.2% |
| Apr 27, 2021 | After the close | 0.32 | 0.35 | +10.9% |
| Feb 23, 2021 | After the close | 0.36 | 0.39 | +8.9% |
| Oct 27, 2020 | After the close | 0.32 | 0.30 | -6.2% |
| Aug 4, 2020 | After the close | 0.22 | 0.25 | +14.7% |
| May 6, 2020 | After the close | 0.21 | 0.24 | +15.7% |
| Mar 4, 2020 | After the close | 0.28 | 0.33 | +15.8% |
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and…